Human Metabolome TechnologiesTSE:6090 +0.84%59 PB Ratio is 1.77 as of Jul. 12, 2026, which is 49% below its 10-year median of 3.50. GuruFocus rates TSE:6090 with a GF Score™ of 59/100 and a GF Value™ of 円529.55 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 196 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 56.63% on this metric.
Human Metabolome Technologies Inc stock PB Ratio (=1.77) is close to 10-year low of 1.72.
The historical rank and industry rank for Human Metabolome Technologies's PB Ratio or its related term are showing as below:
TSE:6090'
s PB Ratio Range Over the Past 10 Years
Min: 1.72 Med: 3.5 Max: 8.67
Current: 1.77
During the past 12 years, Human Metabolome Technologies's highest PB Ratio was 8.67. The lowest was 1.72. And the median was 3.50.
TSE:6090's PB Ratio is ranked better than 56.63% of 196
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.015
vs TSE:6090: 1.77
During the past 12 months, Human Metabolome Technologies's average Book Value Per Share Growth Rate was -1.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 15.50% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -1.00% per year.
During the past 12 years, the highest 3-Year average Book Value Per Share Growth Rate of Human Metabolome Technologies was 100.80% per year. The lowest was -13.60% per year. And the median was 0.90% per year.
Back to Basics: PB Ratio
Human Metabolome Technologies (TSE:6090) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Human Metabolome Technologies PB Ratio Related Terms
Human Metabolome Technologies PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Human Metabolome Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's PB Ratio falls into.
Human Metabolome Technologies PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Human Metabolome Technologies (TSE:6090) has a PB Ratio of 1.77 as of Jul. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Human Metabolome Technologies and its competitors. This is 49% below median its historical median of 3.50. Over the past decade, Human Metabolome Technologies' PB Ratio has ranged from 1.72 to 8.67. According to the industry distribution chart, Human Metabolome Technologies ranks #85 out of 196 companies in the Medical Diagnostics & Research industry, placing it in the top 43.4%.
Is Human Metabolome Technologies' PB Ratio too high?
Human Metabolome Technologies' current PB Ratio of 1.77 is 49% below median its 10-year median of 3.50. Over the past 10 years, this metric has ranged from a low of 1.72 to a high of 8.67. The Medical Diagnostics & Research industry median PB Ratio is 2.02. Human Metabolome Technologies' value of 1.77 is 12.2% below this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #85 out of 196 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #85 out of 196 companies for PB Ratio. This puts Human Metabolome Technologies in the upper half of its industry. The industry median PB Ratio is 2.02. Human Metabolome Technologies' value of 1.77 is 12.2% below this benchmark. Historically, Human Metabolome Technologies' own PB Ratio has ranged from 1.72 to 8.67 over the past decade. While the company's 10-year median is 3.50 vs. the industry median of 2.02, Human Metabolome Technologies has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.02, based on 196 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current PB Ratio of 1.77 is 12.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Human Metabolome Technologies and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current PB Ratio is 1.77, which is 49% below median its own 10-year median of 3.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円529.55, compared to a current price of 円598.00 — trading 12.9% above its estimated fair value. The current PB Ratio is 1.77, which is 49% below median its 10-year median of 3.50 and 12.2% below the Medical Diagnostics & Research industry median of 2.02. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current PB Ratio is 1.77 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued.
The current stock price of 円598.00 is trading 12.9% above its estimated GF Value™ of 円529.55.
GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.
Key valuation signals for TSE:6090:
PB Ratio: 1.77 (49% below median its 10-year median of 3.50)
GF Value™: 円529.55 vs. price of 円598.00 (12.9% above fair value)
Industry Position: 12.2% below the Medical Diagnostics & Research median (#85 of 196)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Human Metabolome Technologies Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
